Citations

Clear

951 citation(s) found for "Cohen, M".

Abstract PL03-03: Real-time multimodal AI enables individualized care in challenging subpopulations
Saria, Suchi, Prasad, Varesh , Beebe-Wang, Nicasia , Zhang, Ellie, Cohen, Neri, Graham, David, Morrison, James, Strand, Jacob, Tallman, Alexandra, Saria, Suchi , Gleber, Conrad D.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: PL03-03-PL03-03

10.1158/1538-7445.am2026-pl03-03 Get It

Abstract Real-time, proactive detection has become a necessity as health systems face converging pressures that legacy tools cannot solve: rising acuity, workforce strain, and persistent quality gaps that erode margins, capacity, and reputation. Clinical decision support has historically lagged because rudimentary rules-based systems drown clinicians in false alerts, eroding trust without reliably changing outcomes at the bedside. Bayesian Health’s real-time clinical intelligence platform was built to close this gap by continuously synthesizing multimodal EHR data (vitals, labs, medications, procedures, and longitudinal history) to learn patient-specific baselines and surface only the most actionable, high-precision signals to care teams. Across diverse health systems, this platform has been used to enable earlier recognition and intervention for a range of high-impact conditions, improving both bedside care and system performance. This talk will focus on concrete, real-world applications of the platform for sepsis, clinical deterioration, and palliative care needs, illustrating how earlier detection and workflow-integrated interventions drive measurable gains in clinical outcomes and margins, and why the value of early, precise detection is amplified in high-risk populations such as oncology patients, whose higher baseline acuity and treatment-related toxicities both elevate their risk of harm and make emerging deterioration harder to recognize. Case Study: Detecting Sepsis within a Oncology Patient Subpopulation. Background: Sepsis remains one of the leading causes of in-hospital mortality, and traditional rules-based alerts have struggled to deliver timely, actionable detection without overwhelming clinicians with false alarms. Oncology patients experience an elevated risk for sepsis and septic shock, and those who experience sepsis are more likely to suffer in-hospital mortality than non-cancer patients with sepsis. Early recognition of sepsis onset is challenging due to the overlap between signs of sepsis and inflammation and tumor- and treatment-related toxicities. We investigated the ability of Bayesian Health’s real-time artificial intelligence-based computational algorithm to perform timely detection of sepsis onset in hospitalized patients with cancer. This algorithm ingests data directly from the electronic health record, such as vital signs, laboratory results, medications, procedures, and patient-specific historical results, processing it in a continuous manner to flag presence of sepsis as early as possible. Methods: Analysis included 7480 adult emergency and inpatient encounters from three tertiary and quaternary academic centers (Cleveland Clinic Main Campus, Sinai Hospital of Baltimore, and Strong Memorial Hospital) and one community hospital (Cleveland Clinic Fairview Hospital) with sufficient data for inclusion (age ≥ 18, presence in an emergency or inpatient care unit, and at least one measurement of a panel of vital signs). Patients with cancer (including subgroups of solid tumor and hematologic malignancy) were identified by current or past recorded diagnoses (ICD-10 codes). All included patient records underwent a multi-tiered retrospective adjudication process. An automated screen labeled records with no evidence of infection or organ dysfunction as non-sepsis, removing them from need for manual review. Two independent physicians then adjudicated a sample of the eliminated records in addition to each remaining record for both presence of sepsis and time of onset, with a third physician reconciling disagreements. Evaluation of the algorithm included all discrete flags generated by the system during a period of time it was not in clinical use and not visible to care teams. Results: In the overall population, 3.1% of all patients and 6.0% of cancer patients were adjudicated to have had sepsis, including zero from a sample of 200 of the records marked as non-sepsis in automated screening. The detection algorithm identified sepsis with high and consistent accuracy across all patients and across cancer patients, including those with solid tumors and with hematologic malignancies (Table). A flag for sepsis occurred in 85.8% of all sepsis patients and 86.1% of cancer patients with sepsis within 4 days of sepsis onset. Sepsis was present in 24.2% of all cancer patients flagged (22.9% of solid tumor patients and 27.9% of hematologic malignancy patients). Compared to patients who were never flagged, all patients who were flagged, whether they had sepsis or not, were more likely to experience in-hospital mortality (7.9% vs 0.3%, p < 0.001) or ICU transfer (38.2% vs 7.9%, p < 0.001). This was also true within oncology patients (in-hospital mortality: 8.8% vs 0.4%, p < 0.001; ICU transfer: 34.7% vs 9.7%, p < 0.001). Implementation of an automated sepsis detection system with high accuracy in populations such as cancer patients, who have elevated risk of poor outcomes following sepsis, provides an opportunity to meaningfully improve timely delivery of care and reduce subsequent morbidity and mortality while minimizing alert fatigue for clinicians. Citation Format: Suchi Saria, Varesh Prasad, Nicasia Beebe-Wang, Ellie Zhang, Neri Cohen, David Graham, Conrad Gleber, James Morrison, Jacob Strand, Alexandra Tallman. Real-time multimodal AI enables individualized care in challenging subpopulations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr PL03-03.
Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy
Vodička, Prokop , El-Galaly, Tarec C, Procházka, Vít , Flowers, Christopher R. , Villa, Diego, Dietrich, Caroline E. , Jakobsen, Lasse Hjort , Ghesquieres, Hervé, Clausen, Michael Roost , Kridel, Robert , Hawkes, Eliza A. , Gandhi, Maher K. , Larson, Melissa C, Cahn, Elliot J, Friedberg, Jonathan W. , Martin, Peter, Cohen, Jonathon B. , Habermann, Thomas M, Wang, Y, Mou, Eric , Belada, David, Mocikova, Heidi, Lossos, Izidore S. , Smedby, Karin E, Sehn, Laurie H, Villa, Diego , Jakobsen, Lasse H , Clausen, Michael Roost , Cheah, Chan Yoon , Hawkes, Eliza , Wahlin, Björn , Chihara, Dai , Cohen, Jonathon B , Casulo, Carla , Wang, Yucai , de Nully Brown, Peter , Mou, Eric , Burack, W Richard , Lossos, Izidore S , Kahl, Brad S , Trnĕný, Marek , Cerhan, James R , Maurer, Matthew , Prochazka, Vit , Kridel, Robert , Gandhi, Maher K , El‐Galaly, Tarec Christoffer , Villa, Diego , Ghesquières, Hervé , Cheah, Chan Y. , Larson, Melissa C. , Cahn, Elliot, Chihara, Dai , Habermann, Thomas M. , Casulo, Carla , Brown, Peter de Nully , Belada, David , Janikova, Andrea , Móciková, Heidi , Burack, Richard , Kahl, Brad S. , Smedby, Karin E. , Sehn, Laurie H. , Trněný, Marek , Cerhan, James R. , Maurer, Matthew J. , Vodicka, Prokop

Mayo Clinic

Blood | April 14, 2026 | Volume: 147 | Issue: 26 | Pages: 3248-3252

10.1182/blood.2026033090 | PMID 41980013 Get It

Abstract A short diagnosis-to-treatment interval independently predicts inferior outcomes in follicular lymphoma. Using international discovery and validation cohorts, we demonstrate its prognostic value beyond established prognostic indices, with implications for risk stratification, clinical trial design, and interpretation.
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025
Danilov, Alexey V. , Coombs, Catherine C., Phillips, Tycel, Allan, John N. , Barrientos, Jacqueline C. , Choi, Michael Y. , Cohen, J. B., Hill, Brian T., Karmali, Reem, Patel, Krish, Sauter, Craig S. , Strati, Paolo, Shadman, Mazyar, Cohen, Jonathon B , Wang, Yucai , Barrientos, Jacqueline , Phillips, Tycel , Barta, Stefan K , Hill, Brian T. , Karmali, Reem , Patel, Krish , Rhodes, Joanna , Strati, Paolo , Wang, Yucai , Shadman, Mazyar

Mayo Clinic

Cancer | April 9, 2026 | Volume: 132 | Issue: 8 | Pages: No page available

10.1002/cncr.70389 | PMID 41955632 Get It

Abstract The Bridging the Gaps (BTG) in Leukemia, Lymphoma and Multiple Myeloma Consensus Conference 2025 brought together a multidisciplinary group of oncology experts to address the complexities of lymphoma management, focusing on mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B‐cell lymphoma (DLBCL). This article presents consensus recommendations developed through a modified Delphi process, which emphasize the need for tailored therapeutic strategies in light of recent advancements in treatment options. Key recommendations include the screening for high‐risk features in MCL, use of the BOVen regimen (zanubrutinib, obinutuzumab, and venetoclax) for TP53 ‐aberrant cases, and integration of chimeric antigen receptor T‐cell therapy for patients with mantle cell lymphoma that is refractory to covalent Bruton tyrosine kinase inhibitors. For CLL, recommendations include consideration of time‐limited therapies for younger patients and a “watch and wait” strategy for asymptomatic patients despite the improved activity and safety of current treatment regimens. For DLBCL, this article highlights the challenges in treatment sequencing and the role of circulating tumor DNA and minimal residual disease testing in monitoring disease progression. Overall, the conference describes the importance of ongoing research to refine management strategies and improve patient outcomes in lymphoma care, addressing the gaps in clinical practice where high‐level evidence is lacking.
The Clinical Characteristics and Outcomes of Multiple Myeloma Patients With Oligo or Non–Secretory Relapse—A Retrospective Cohort Study
Zamir, Itai, Cohen, Inbar , Fridberg, Gil , Shragai, Tamir , Trestman, Svetlana, Ziv‐Baran, Tomer , Shmuel, Ronit, Melamed, Natan, Levy, Shai , Avivi, Irit, Raanani, Pia, Dispenzieri, Angela, Gertz, Morie A., Cohen, Yaël C. , Vaxman, Iuliana , Shragai, Tamir , Levy, Shai , Gertz, Morie A , Vaxman, Iuliana , Luttwak, Efrat , Avivi, I., Raanani, Pia , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

Hematological Oncology | April 7, 2026 | Volume: 44 | Issue: 3 | Pages: No page available

10.1002/hon.70192 | PMID 41944077 Get It

ABSTRACT Oligo‐secretory and non‐secretory MM present a clinical challenge due to the difficulties in initial diagnosis, response to treatment assessment, and relapse detection. They are excluded from most clinical trials, which typically require measurable disease. We describe the characteristics and outcomes of 86 patients with secretory myeloma at diagnosis who developed an OSR, matched 1:1 to a cohort with secretory relapse (SR). With a median follow‐up of 9.3 years, 16.6% (48/289) of evaluable patients developed an OSR. Lower levels of light chains at presentation, and younger age are predictive of an OSR. The median OS since relapse of the OSR group was 4.01 (95% CI 1.625–6.395) versus 3.25 (95% CI 2.255–4.245) years in the SR control group ( p = 0.4). A third of our OSR cohort had a subsequent SR. We did not find any predictive factor for SR after OSR. The median OS of the subgroup of patients who developed a SR after OSR was 3.35 years (95% CI 1.541–5.159), versus 5.8 years (95% CI 2.072–9.528) in the group that remained oligo‐secretory ( p = 0.336). The median TTNT of the SR after OSR group was 1.68 years (95% CI 0.341–0.919) versus 4.58 (95% CI not reached‐not reached) in the group that remained oligo‐secretory ( p < 0.001).
The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome
Shemtov, Sarah J. , McGann, Eric, Carrillo, Lucy , Lee, Sangmin , Anson, Herbert, Chung, Claire S, Weinert, Jaye L., Anagnostou, Maria-Eleni, Lai, Guan-Ju, Verheijen, Bert M. , Wan, Junxiang , Vorobyova, Ivetta, Sanchez-Contreras, Monica, Conover, Cheryl A. , Thorwald, Max A. , Cohen, P., Kennedy, Scott R. , Goût, Jean-François , Haroon, Suraiya , Vermulst, Marc , Hwang, Eric , Chung, Claire S , Weinert, Jaye L , Lai, Guan-Ju D , Conover, Cheryl A , Thorwald, Max A , Cohen, Pinchas , Kennedy, Scott R , Gout, Jean-François , Vermulst, Marc , Anagnostou, Maria‐Eleni, Sánchez-Contreras, Mónica , Cohen, Pinchas

Mayo Clinic

Science Advances | April 3, 2026 | Volume: 12 | Issue: 14 | Pages: No page available

10.1126/sciadv.aea4279 | PMID 41931604 Get It

Suppression of insulin-like growth factor-1 (IGF-1) signaling extends mammalian life span and protects against a range of age-related diseases. Unexpectedly, we found that reduced IGF-1 signaling fails to extend the life span of mitochondrial mutator mice. Most of the longevity pathways that are normally initiated by IGF-1 suppression were either blocked or blunted in the mutator mice. These observations suggest that the prolongevity effects of IGF-1 suppression critically depend on the integrity of the mitochondrial genome, revealing an unexpected hierarchy in the pathways that control mammalian aging. Together, these findings deepen our understanding of the interactions between the hallmarks of aging and underscore the need for interventions that preserve the integrity of the mitochondrial genome.
Predicting Leg Length Change After Valgus-Correcting Lateral Opening-Wedge Versus Medial Closing-Wedge Distal Femoral Osteotomy
Elias, Tristan J. , Haneberg, Erik , Brusalis, Christopher M., Forlenza, Enrico, Kogan, Monica , Krych, Aaron J., Yanke, Adam B., Krych, Aaron J. , Haneberg, Erik C , Kaleka, Camila Cohen , Krych, Aaron J , Yanke, Adam B , Brusalis, Christopher M. , Phillips, Andrew , Wang, Allen S. , Forlenza, Enrico M. , Yanke, Adam B.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | April 1, 2026 | Volume: 14 | Issue: 4 | Pages: No page available

10.1177/23259671251414156 | PMID 41943807 Get It

Background: Distal femoral osteotomy (DFO) may be performed via either a lateral opening-wedge (LOW) or medial closing-wedge (MCW) osteotomy with meaningful clinical improvements; however, the effects of each DFO technique on leg length have not been well characterized. Purpose: To (1) validate a radiographic measurement technique to predict leg length changes after DFO and (2) compare the change in leg length after DFO for the LOW and MCW techniques. Study Design: Cohort study; Level of evidence, 3. Methods: Preoperative and postoperative full-length standing radiographs obtained from patients who underwent DFO at 1 of 2 academic medical centers were evaluated. The region on the medial (for LOW) or lateral (for MCW) distal femur cortex that would be the “hinge point” during DFO was identified on the radiographs. The distance from the center of the femoral head to the hinge point ( A ), the distance from the hinge point to the center of the talus ( B ), and the resultant angle (α) were measured. The equation presented within the text was used to plot the predicted leg length changes corresponding to the change in alpha angle produced by DFO. Comparisons were made between (1) the predicted and measured leg length changes after DFO and (2) the measured leg length change after LOW versus MCW osteotomies. Results: For both LOW (n = 10) and MCW (n = 10) osteotomies, the predicted leg length change was equivalent to the true change measured on postoperative radiographs (LOW: P = .16; MCW: P = .85). There was a mean lengthening of 0.85 mm (range, 0.5-1.3 mm) for every 1° of mechanical axis correction with LOW DFO, compared to a mean shortening of 0.45 mm (range, 0.1-1.4 mm) per 1° of MCW correction. Conclusion: Preoperative radiographic imaging can be used to predict leg length change after DFO with high reliability. Surgeons can expect approximately 0.85 mm of lengthening per 1° of DFO correction when performing LOW osteotomies, compared to 0.45 mm of shortening per 1° of correction for MCW osteotomies. However, the most accurate prediction results from patient-specific calculations.
Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative
Paredes, Anghela Z. , Beckhorn, Catherine B , Fusco, Joseph , McKay, Katlyn G. , Kontchou, Nelly‐Ange T. , Kastenberg, Zachary J. , Roach, Jonathan P. , Myers, Emily K. , Cost, Nicholas G. , Mullapudi, Bhargava , Jensen, Amanda , Dasgupta, Roshni, Lundstedt, John, Brungardt, Joseph G. , Davidoff, Andrew M., Murphy, Andrew J., Piché, Nelson , Le‐Nguyen, Annie, Craig, Brian T. , Schuh, Jennifer M , Cromeens, Barrett P., Lopez, A. Javier, Mello, Kelsey , Short, Joshua , Petroze, Robin T. , Rajavel, Shay, Thompson, Grace R., Fialkowski, Elizabeth , Fowler, Kathryn , Martchenke, Nathan, Rich, Barrie S. , Glick, Richard D. , Doyle, Kathleen , Abril, Paige, Seemann, Natashia M. , Davidson, Jacob B., Wilson, Claire A. , Joshi, Devashish , Stellon, Michael , Hammoud, Maya M. , Williams, Keyonna M , Grant, Christa N. , Gorgy, Merit, Debertin, Julia , Cameron, Danielle B. , Stetson, Alyssa , Lee, William G., Barkhordar, Aaron, Austin, Mary, Coakley, Brian A. , Murphy, Joseph T., Pitonak, M., Boehmer, Chloé , Beckhorn, Catherine , Kastenberg, Zachary J , Lautz, Timothy , Brungardt, Joseph G , Murphy, Andrew J , Thompson, Grace R , Glick, Richard D , Seemann, Natashia M , Joshi, Devashish , Stellon, Michael , Dimmer, Alexandra M , Williams, Keyonna , Polites, Stephanie F. , Stetson, Alyssa , Lee, William G , Barkhordar, Aaron , Malek, Marcus M , Rinehardt, Hannah , Tracy, Elisabeth T. , Leraas, Harold J. , Hoyt, David , Marchese, Charles R. , Lautz, Timothy B. , Carter, Michela M. , Dasgupta, Roshni , Talbot, Lindsay J , Davidoff, Andrew M. , Aldrink, Jennifer H. , Mansfield, Sara A. , Lal, Dave R. , Mannava, Sindhu V , Castle, Shannon L. , Lopez, Adriana, Rajavel, Shay , Mattei, Peter , Rothstein, David H. , Fowler, Kathryn, Brown, Erin G. , Le, Hau D. , Ahmed, Tamer, Ehrlich, Peter F. , Gorgy, Merit , Kim, Eugene S. , Kahan, Anastasia M , Murphy, Joseph T., Malek, Marcus M.

Mayo Clinic

Pediatric Blood & Cancer | March 27, 2026 | Volume: 73 | Issue: 6 | Pages: No page available

10.1002/1545-5017.70296 | PMID 41889149 Get It

ABSTRACT Purpose Malignant rhabdoid tumor of the kidney (MRTK) is a rare, aggressive tumor seen in young children. The optimal timing of resection for locally advanced tumors is not well‐defined. The purpose of this study is to evaluate modern oncologic outcomes and the impact of surgical timing. Methods A multicenter retrospective review was performed by institutions participating in the Pediatric Surgical Oncology Research Collaborative. Children younger than 21 years old with MRTK diagnosed between 2000 and 2022 were included. Results Sixty‐nine patients were identified with MRTK and met the inclusion criteria. Median age of diagnosis was 10.1 months. Overall survival (OS) at 1, 5, and 10 years was 49%, 32%, and 19%, respectively. Patients with local Stage III disease who underwent upfront resection ( n = 18) compared to those who had delayed resection after NAT ( n = 15) had a similar OS, median OS greater than 60 months versus 14.6 months, respectively; p = 0.396. The surgical timing groups were balanced in terms of the presence of metastasis, length of follow‐up, and tumor characteristics. There was one occurrence of primary intraoperative tumor spill and two occurrences of organ injury in the upfront resection group compared to none in the delayed resection group. Conclusion MRTK carries a poor prognosis despite multimodal treatment. Histologic diagnosis may not be confirmed at presentation, and MRTK cannot be reliably distinguished from Wilms tumor on imaging alone. As overall survival is similar, the decision regarding surgical timing in locally advanced tumors should be individualized based on perceived resectability, balancing the risk of intraoperative complications against the possibility of tumor progression during neoadjuvant therapy.
The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
Goldberg, Joseph F. , McIntyre, Roger S. , Mago, Rajnish, Jha, Manish K. , Berk, Michael , Kasper, Siegfried , Freeman, Marlene P. , GITLIN, MICHAEL J., Ostacher, Michael J. , Citrome, Leslie, Iosifescu, Dan V., Thase, Michael E., Young, Allan H. , Tohen, Mauricio, Nierenberg, Andrew A., Macaluso, Matt, Shelton, Richard C., Correll, Christoph U., Rosenblat, Joshua D., Gorwood, Philip, Khan, Arifulla, Kupka, Ralph, Cohen, Lawrence J., Mitchell, Philip B., Frye, Mark A., Sanacora, Gerard, Kane, John M., D, Goodman, Zohar, Joseph, Davis, Lori, Gupta, Swapnil , Steingard, Sandra , Zarate, Carlos A., Clayton, Anita H., Cohen, Lawrence J. , McIntyre, Roger S , Malhi, Gin S , Jha, Manish K , Berk, Michael , Kasper, Siegfried , Sajatovic, Martha , Ostacher, Michael J , Perlis, Roy H , Furukawa, Toshi A , Vieta, E , Young, Allan H , Aaronson, Scott T , Rubio, Jose M , Swartz, Holly A. , Malhi, Gin S. , Gitlin, Michael , Citrome, Leslie , Vieta, Eduard , Thase, Michael E. , Tohen, Mauricio , Nierenberg, Andrew A. , Shelton, Richard C. , Correll, Christoph Ulrich , Rosenblat, Joshua D. , Gorwood, Philip , Kupka, Ralph , Mitchell, Philip B , Frye, Mark A. , Sanacora, Gerard , Kane, John M., Zohar, Joseph , Davis, Lori L. , Gupta, Swapnil, Zarate, Carlos A. , Clayton, Anita H.

Mayo Clinic

The British Journal of Psychiatry | March 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1192/bjp.2026.10580 | PMID 41877318 Get It

Summary The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.